Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings results on February 17, 2026 that fell short of analyst expectations. The Healthcare company reported earnings per…
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings results on February 17, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.24, missing the consensus estimate of $2.15 by $2.39 per share. Revenue came in at $451.8M, beating the estimate of $447.1M.
Halozyme Therapeutics's stock moved following the earnings release. The stock currently trades at $75.04 with a market capitalization of $7.3B.
Current market data
NASDAQ · HALO
$105.35
Down: -$1.57 · -1.47%
Live quote updated
Our Markets Team monitors market data, SEC filings, analyst actions, earnings releases, and corporate announcements to produce timely updates for investors.
Keep reading
price ·
earnings ·
analyst ·
sec_filing ·
